-
1
-
-
39949083194
-
Schizophrenia, "Just the Facts": What we know in 2008 part 1: Overview
-
Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, "Just the Facts": what we know in 2008 part 1: overview. Schizophr Res 2008; 100(1-3): 4-19.
-
(2008)
Schizophr Res
, vol.100
, Issue.1-3
, pp. 4-19
-
-
Tandon, R.1
Keshavan, M.S.2
Nasrallah, H.A.3
-
3
-
-
33845797866
-
Negative symptoms of schizophrenia: A problem that will not go away
-
Stahl SM, Buckley PF. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatrica Scand 2007; 115: 4-11.
-
(2007)
Acta Psychiatrica Scand
, vol.115
, pp. 4-11
-
-
Stahl, S.M.1
Buckley, P.F.2
-
4
-
-
84863866584
-
Negative symptoms and psychosocial functioning in schizophrenia: Neglected but important targets for treatment
-
Hunter R, Barry S. Negative symptoms and psychosocial functioning in schizophrenia: Neglected but important targets for treatment. Eur Psychiatry 2012; 27(6): 432-6.
-
(2012)
Eur Psychiatry
, vol.27
, Issue.6
, pp. 432-436
-
-
Hunter, R.1
Barry, S.2
-
5
-
-
70449641202
-
Second-generation antipsychotics for schizophrenia: Can we resolve the conflict?
-
Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med 2009; 39: 1591-602.
-
(2009)
Psychol Med
, vol.39
, pp. 1591-1602
-
-
Leucht, S.1
Kissling, W.2
Davis, J.M.3
-
6
-
-
34548548362
-
Clinical evaluation of negative symptoms in schizophrenia
-
Moller HJ. Clinical evaluation of negative symptoms in schizophrenia. Eur Psychiatry 2007; 22: 380-6.
-
(2007)
Eur Psychiatry
, vol.22
, pp. 380-386
-
-
Moller, H.J.1
-
7
-
-
0017255979
-
Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
-
Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192: 481-3.
-
(1976)
Science
, vol.192
, pp. 481-483
-
-
Creese, I.1
Burt, D.R.2
Snyder, S.H.3
-
8
-
-
0028850552
-
Glutamate receptor dysfunction and schizophrenia
-
Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998-1007.
-
(1995)
Arch Gen Psychiatry
, vol.52
, pp. 998-1007
-
-
Olney, J.W.1
Farber, N.B.2
-
9
-
-
77149138329
-
Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: Too little juice or a miswired brain?
-
Marek GJ, Behl B, Bespalov AY, et al. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Mol Pharmacol 2010; 77: 317-26.
-
(2010)
Mol Pharmacol
, vol.77
, pp. 317-326
-
-
Marek, G.J.1
Behl, B.2
Bespalov, A.Y.3
-
10
-
-
77956648156
-
N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia?
-
Kantrowitz JT, Javitt DC. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull 2010; 83: 108-21.
-
(2010)
Brain Res Bull
, vol.83
, pp. 108-121
-
-
Kantrowitz, J.T.1
Javitt, D.C.2
-
11
-
-
78149284957
-
Glycine transport inhibitors for the treatment of schizophrenia
-
Hashimoto K. Glycine transport inhibitors for the treatment of schizophrenia. Open Med Chem J 2010; 4: 10-9.
-
(2010)
Open Med Chem J
, vol.4
, pp. 10-19
-
-
Hashimoto, K.1
-
12
-
-
0023091647
-
Glycine potentiates the NMDA response in cultured mouse brain neurons
-
Johnson JW, Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987; 325: 529-31.
-
(1987)
Nature
, vol.325
, pp. 529-531
-
-
Johnson, J.W.1
Ascher, P.2
-
13
-
-
0032429754
-
Glycine and N-methyl-D-aspartate receptors: Physiological significance and possible therapeutic applications
-
Danysz W, Parsons CG. Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 1998; 50: 597-664.
-
(1998)
Pharmacol Rev
, vol.50
, pp. 597-664
-
-
Danysz, W.1
Parsons, C.G.2
-
14
-
-
0023754192
-
Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes
-
Kleckner NW, Dingledine R. Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science 1988; 241: 835-7.
-
(1988)
Science
, vol.241
, pp. 835-837
-
-
Kleckner, N.W.1
Dingledine, R.2
-
15
-
-
84864634182
-
Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists
-
Papouin T, Ladépêche L, Ruel J, et al. Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 2012; 150(3): 633-46.
-
(2012)
Cell
, vol.150
, Issue.3
, pp. 633-646
-
-
Papouin, T.1
Ladépêche, L.2
Ruel, J.3
-
16
-
-
84863337898
-
Opposing roles of synaptic and extrasynaptic NMDA receptor signaling in cocultured striatal and cortical neurons
-
Kaufman AM, Milnerwood AJ, Sepers MD, et al. Opposing roles of synaptic and extrasynaptic NMDA receptor signaling in cocultured striatal and cortical neurons. J Neurosci 2012; 32(12): 3992-4003.
-
(2012)
J Neurosci
, vol.32
, Issue.12
, pp. 3992-4003
-
-
Kaufman, A.M.1
Milnerwood, A.J.2
Sepers, M.D.3
-
17
-
-
84863148838
-
Functional roles of synaptic and extrasynaptic NMDA receptors in physiological and pathological neuronal activities
-
Li ST, Ju JG. Functional roles of synaptic and extrasynaptic NMDA receptors in physiological and pathological neuronal activities. Curr Drug Targets 2012; 13(2): 207-21.
-
(2012)
Curr Drug Targets
, vol.13
, Issue.2
, pp. 207-221
-
-
Li, S.T.1
Ju, J.G.2
-
18
-
-
80053221118
-
Translating glutamate: From pathophysiology to treatment
-
Javitt DC, Schoepp D, Kalivas PW, et al. Translating glutamate: from pathophysiology to treatment. Sci Transl Med 2011; 3(102): 102mr2.
-
(2011)
Sci Transl Med
, vol.3
, Issue.102
-
-
Javitt, D.C.1
Schoepp, D.2
Kalivas, P.W.3
-
19
-
-
34547634946
-
Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis
-
Enomoto T, Noda Y, Nabeshima T. Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis. Methods Find Exp Clin Pharmacol 2007; 29(4): 291-301.
-
(2007)
Methods Find Exp Clin Pharmacol
, vol.29
, Issue.4
, pp. 291-301
-
-
Enomoto, T.1
Noda, Y.2
Nabeshima, T.3
-
20
-
-
0019293020
-
Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia
-
Kim JS, Kornhuber HH, Schmid-Burgk W, et al. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 1980; 20: 379-82.
-
(1980)
Neurosci Lett
, vol.20
, pp. 379-382
-
-
Kim, J.S.1
Kornhuber, H.H.2
Schmid-Burgk, W.3
-
21
-
-
12344327212
-
Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence
-
Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005; 10: 40-68.
-
(2005)
Mol Psychiatry
, vol.10
, pp. 40-68
-
-
Harrison, P.J.1
Weinberger, D.R.2
-
22
-
-
68549099832
-
Positive and negative symptoms in schizophrenia: The NMDA receptor hypofunction hypothesis, neuregulin/ErbB4 and synapse regression
-
Bennett M. Positive and negative symptoms in schizophrenia: the NMDA receptor hypofunction hypothesis, neuregulin/ErbB4 and synapse regression. Aust N Z J Psychiatry 2009; 43(8): 711-21.
-
(2009)
Aust N Z J Psychiatry
, vol.43
, Issue.8
, pp. 711-721
-
-
Bennett, M.1
-
23
-
-
0025952455
-
Recent advances in the phencyclidine model of schizophrenia
-
Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-8.
-
(1991)
Am J Psychiatry
, vol.148
, pp. 1301-1308
-
-
Javitt, D.C.1
Zukin, S.R.2
-
24
-
-
0001979163
-
Comparison of phencyclidine hydrochloride (Sernyl) with other drugs. Simulation of schizophrenic performance with phencyclidine hydrochloride (Sernyl), lysergic acid diethylamide (LSD-25), and amobarbital (Amytal) sodium; II. Symbolic and sequential thinking
-
Cohen BD, Rosenbaum G, Luby ED, et al. Comparison of phencyclidine hydrochloride (Sernyl) with other drugs. Simulation of schizophrenic performance with phencyclidine hydrochloride (Sernyl), lysergic acid diethylamide (LSD-25), and amobarbital (Amytal) sodium; II. Symbolic and sequential thinking. Arch Gen Psychiatry 1962; 6: 395-401.
-
(1962)
Arch Gen Psychiatry
, vol.6
, pp. 395-401
-
-
Cohen, B.D.1
Rosenbaum, G.2
Luby, E.D.3
-
26
-
-
70449270240
-
Comparison of sernyl with other drugs: Simulation of schizophrenic performance with sernyl, LSD-25, and amobarbital (amytal) sodium; I. Attention, motor function, and proprioception
-
Rosenbaum G, Cohen BD, Luby ED, et al. Comparison of sernyl with other drugs: simulation of schizophrenic performance with sernyl, LSD-25, and amobarbital (amytal) sodium; I. Attention, motor function, and proprioception. AMA Arch Gen Psychiatry 1959; 1: 651-6.
-
(1959)
AMA Arch Gen Psychiatry
, vol.1
, pp. 651-656
-
-
Rosenbaum, G.1
Cohen, B.D.2
Luby, E.D.3
-
28
-
-
0029927565
-
NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers
-
Malhotra AK, Pinals DA, Weingartner H, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996; 14: 301-7.
-
(1996)
Neuropsychopharmacology
, vol.14
, pp. 301-307
-
-
Malhotra, A.K.1
Pinals, D.A.2
Weingartner, H.3
-
29
-
-
84858154998
-
NMDA antagonists recreate signal-to-noise ratio and timing perturbations present in schizophrenia
-
Saunders JA, Gandal MJ, Siegel SJ. NMDA antagonists recreate signal-to-noise ratio and timing perturbations present in schizophrenia. Neurobiol Dis 2012; 46: 93-100.
-
(2012)
Neurobiol Dis
, vol.46
, pp. 93-100
-
-
Saunders, J.A.1
Gandal, M.J.2
Siegel, S.J.3
-
30
-
-
0036501435
-
Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers
-
Umbricht D, Koller R, Vollenweider FX, Schmid L. Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol Psychiatry 2002; 51(5): 400-6.
-
(2002)
Biol Psychiatry
, vol.51
, Issue.5
, pp. 400-406
-
-
Umbricht, D.1
Koller, R.2
Vollenweider, F.X.3
Schmid, L.4
-
31
-
-
0014201598
-
Association of glycine with spinal interneurones
-
Davidoff RA, Shank RP, Graham LT, Jr. et al. Association of glycine with spinal interneurones. Nature 1967; 214: 680-1.
-
(1967)
Nature
, vol.214
, pp. 680-681
-
-
Davidoff, R.A.1
Shank, R.P.2
Graham Jr., L.T.3
-
32
-
-
84890882915
-
Localization of glycine receptors in the human forebrain, brainstem, and cervical spinal cord: An immunohistochemical review
-
Baer K, Waldvogel HJ, Faull RL, et al. Localization of glycine receptors in the human forebrain, brainstem, and cervical spinal cord: an immunohistochemical review. Front Mol Neurosci 2009; 2: 25.
-
(2009)
Front Mol Neurosci
, vol.2
, pp. 25
-
-
Baer, K.1
Waldvogel, H.J.2
Faull, R.L.3
-
33
-
-
4644265039
-
Molecular structure and function of the glycine receptor chloride channel
-
Lynch JW. Molecular structure and function of the glycine receptor chloride channel. Physiol Rev 2004; 84: 1051-95.
-
(2004)
Physiol Rev
, vol.84
, pp. 1051-1095
-
-
Lynch, J.W.1
-
34
-
-
0037074985
-
Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits
-
Chatterton JE, Awobuluyi M, Premkumar LS, et al. Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits. Nature 2002; 415(6873): 793-8.
-
(2002)
Nature
, vol.415
, Issue.6873
, pp. 793-798
-
-
Chatterton, J.E.1
Awobuluyi, M.2
Premkumar, L.S.3
-
35
-
-
70949105241
-
Glycine as a neurotransmitter in the forebrain: A short review
-
Hernandes MS, Troncone LR. Glycine as a neurotransmitter in the forebrain: a short review. J Neural Transm 2009; 116: 1551-60.
-
(2009)
J Neural Transm
, vol.116
, pp. 1551-1560
-
-
Hernandes, M.S.1
Troncone, L.R.2
-
36
-
-
0031056559
-
Cell-type specific organization of glycine receptor clusters in the mammalian spinal cord
-
Alvarez FJ, Dewey DE, Harrington DA, et al. Cell-type specific organization of glycine receptor clusters in the mammalian spinal cord. J Comp Neurol 1997; 379: 150-70.
-
(1997)
J Comp Neurol
, vol.379
, pp. 150-170
-
-
Alvarez, F.J.1
Dewey, D.E.2
Harrington, D.A.3
-
37
-
-
20444391684
-
Glycine transporters: Essential regulators of neurotransmission
-
Eulenburg V, Armsen W, Betz H, et al. Glycine transporters: essential regulators of neurotransmission. Trends Biochem Sci 2005; 30: 325-33.
-
(2005)
Trends Biochem Sci
, vol.30
, pp. 325-333
-
-
Eulenburg, V.1
Armsen, W.2
Betz, H.3
-
38
-
-
0029014595
-
Regional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS
-
Zafra F, Gomeza J, Olivares L, et al. Regional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS. Eur J Neurosci 1995; 7: 1342-52.
-
(1995)
Eur J Neurosci
, vol.7
, pp. 1342-1352
-
-
Zafra, F.1
Gomeza, J.2
Olivares, L.3
-
39
-
-
15244347525
-
Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain
-
Cubelos B, Gimenez C, Zafra F. Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain. Cereb Cortex 2005; 15: 448-59.
-
(2005)
Cereb Cortex
, vol.15
, pp. 448-459
-
-
Cubelos, B.1
Gimenez, C.2
Zafra, F.3
-
40
-
-
0024535309
-
Characteristics and adaptive regulation of glycine transport in cultured glial cells
-
Zafra F, Gimenez C. Characteristics and adaptive regulation of glycine transport in cultured glial cells. Biochem J 1989; 258: 403-8.
-
(1989)
Biochem J
, vol.258
, pp. 403-408
-
-
Zafra, F.1
Gimenez, C.2
-
41
-
-
0028860260
-
Localization of glycine neurotransmitter transporter (GLYT2) reveals correlation with the distribution of glycine receptor
-
Jursky F, Nelson N. Localization of glycine neurotransmitter transporter (GLYT2) reveals correlation with the distribution of glycine receptor. J Neurochem 1995; 64: 1026-33.
-
(1995)
J Neurochem
, vol.64
, pp. 1026-1033
-
-
Jursky, F.1
Nelson, N.2
-
42
-
-
10744221393
-
Inactivation of the glycine transporter 1 gene discloses vital role of glial glycine uptake in glycinergic inhibition
-
Gomeza J, Hulsmann S, Ohno K, et al. Inactivation of the glycine transporter 1 gene discloses vital role of glial glycine uptake in glycinergic inhibition. Neuron 2003; 40: 785-96.
-
(2003)
Neuron
, vol.40
, pp. 785-796
-
-
Gomeza, J.1
Hulsmann, S.2
Ohno, K.3
-
43
-
-
55749110913
-
The glycine transporter GlyT2 controls the dynamics of synaptic vesicle refilling in inhibitory spinal cord neurons
-
Rousseau F, Aubrey KR, Supplisson S. The glycine transporter GlyT2 controls the dynamics of synaptic vesicle refilling in inhibitory spinal cord neurons. J Neurosci 2008; 28: 9755-68.
-
(2008)
J Neurosci
, vol.28
, pp. 9755-9768
-
-
Rousseau, F.1
Aubrey, K.R.2
Supplisson, S.3
-
44
-
-
0030919910
-
Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes
-
Supplisson S, Bergman C. Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes. J Neurosci 1997; 17: 4580-90.
-
(1997)
J Neurosci
, vol.17
, pp. 4580-4590
-
-
Supplisson, S.1
Bergman, C.2
-
45
-
-
3042542923
-
Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels
-
Martina M, Gorfinkel Y, Halman S, et al. Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels. J Physiol 2004; 557: 489-500.
-
(2004)
J Physiol
, vol.557
, pp. 489-500
-
-
Martina, M.1
Gorfinkel, Y.2
Halman, S.3
-
46
-
-
0036455132
-
Potentiation of inhibitory glycinergic neurotransmission by Zn2+: A synergistic interplay between presynaptic P2X2 and postsynaptic glycine receptors
-
Laube B. Potentiation of inhibitory glycinergic neurotransmission by Zn2+: a synergistic interplay between presynaptic P2X2 and postsynaptic glycine receptors. Eur J Neurosci 2002; 16: 1025-36.
-
(2002)
Eur J Neurosci
, vol.16
, pp. 1025-1036
-
-
Laube, B.1
-
47
-
-
77953289841
-
D-Serine and a glycine transporter-1 inhibitor enhance social memory in rats
-
Shimazaki T, Kaku A, Chaki S. D-Serine and a glycine transporter-1 inhibitor enhance social memory in rats. Psychopharmacology (Berl) 2010; 209: 263-70.
-
(2010)
Psychopharmacology (Berl)
, vol.209
, pp. 263-270
-
-
Shimazaki, T.1
Kaku, A.2
Chaki, S.3
-
48
-
-
0029658545
-
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia
-
Heresco-Levy U, Javitt DC, Ermilov M, et al. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 1996; 169: 610-7.
-
(1996)
Br J Psychiatry
, vol.169
, pp. 610-617
-
-
Heresco-Levy, U.1
Javitt, D.C.2
Ermilov, M.3
-
49
-
-
0032925438
-
Efficacy of highdose glycine in the treatment of enduring negative symptoms of schizophrenia
-
Heresco-Levy U, Javitt DC, Ermilov M, et al. Efficacy of highdose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999; 56: 29-36.
-
(1999)
Arch Gen Psychiatry
, vol.56
, pp. 29-36
-
-
Heresco-Levy, U.1
Javitt, D.C.2
Ermilov, M.3
-
50
-
-
0348047434
-
Comparative effects of glycine and Dcycloserine on persistent negative symptoms in schizophrenia: A retrospective analysis
-
Heresco-Levy U, Javitt DC. Comparative effects of glycine and Dcycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr Res 2004; 66: 89-96.
-
(2004)
Schizophr Res
, vol.66
, pp. 89-96
-
-
Heresco-Levy, U.1
Javitt, D.C.2
-
51
-
-
51049089047
-
Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas
-
Perry KW, Falcone JF, Fell MJ, et al. Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas. Neuropharmacology 2008 55(5): 743-54.
-
(2008)
Neuropharmacology
, vol.55
, Issue.5
, pp. 743-754
-
-
Perry, K.W.1
Falcone, J.F.2
Fell, M.J.3
-
52
-
-
0041920952
-
The glycine transporter type 1 inhibitor N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior
-
Kinney GG, Sur C, Burno M, et al. The glycine transporter type 1 inhibitor N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J Neurosci 2003; 23: 7586-91.
-
(2003)
J Neurosci
, vol.23
, pp. 7586-7591
-
-
Kinney, G.G.1
Sur, C.2
Burno, M.3
-
53
-
-
0842286593
-
Reversal of phencyclidineinduced dopaminergic dysregulation by N-methyl-D-aspartate receptor/ glycine-site agonists
-
Javitt DC, Balla A, Burch S, et al. Reversal of phencyclidineinduced dopaminergic dysregulation by N-methyl-D-aspartate receptor/ glycine-site agonists. Neuropsychopharmacology 2004; 29(2): 300-7.
-
(2004)
Neuropsychopharmacology
, vol.29
, Issue.2
, pp. 300-307
-
-
Javitt, D.C.1
Balla, A.2
Burch, S.3
-
54
-
-
29744453122
-
Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic
-
Depoortere R, Dargazanli G, Estenne-Bouhtou G, et al. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 2005; 30: 1963-85.
-
(2005)
Neuropsychopharmacology
, vol.30
, pp. 1963-1985
-
-
Depoortere, R.1
Dargazanli, G.2
Estenne-Bouhtou, G.3
-
55
-
-
29744432669
-
2-Chloro-N-[(S)-phenyl [(2S)-piperidin-2-yl] methyl]-3-trifluoromethyl benzamide, mono hydrochloride, an inhibitor of the glycine transporter type 1, increases evoked-dopamine release in the rat nucleus accumbens in vivo via an enhanced glutamatergic neurotransmission
-
Leonetti M, Desvignes C, Bougault I, et al. 2-Chloro-N-[(S)-phenyl [(2S)-piperidin-2-yl] methyl]-3-trifluoromethyl benzamide, mono hydrochloride, an inhibitor of the glycine transporter type 1, increases evoked-dopamine release in the rat nucleus accumbens in vivo via an enhanced glutamatergic neurotransmission. Neuroscience 2006; 137: 555-64.
-
(2006)
Neuroscience
, vol.137
, pp. 555-564
-
-
Leonetti, M.1
Desvignes, C.2
Bougault, I.3
-
56
-
-
59449096382
-
The glycine transporter 1 inhibitor SSR504734 enhances working memory performance in a continuous delayed alternation task in C57BL/6 mice
-
Singer P, Yee BK, Feldon J, et al. The glycine transporter 1 inhibitor SSR504734 enhances working memory performance in a continuous delayed alternation task in C57BL/6 mice. Psychopharmacology (Berl) 2009; 202: 371-84.
-
(2009)
Psychopharmacology (Berl)
, vol.202
, pp. 371-384
-
-
Singer, P.1
Yee, B.K.2
Feldon, J.3
-
57
-
-
59449086656
-
Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: Latent inhibition studies in the rat
-
Black MD, Varty GB, Arad M, et al. Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology (Berl) 2009; 202: 385-96.
-
(2009)
Psychopharmacology (Berl)
, vol.202
, pp. 385-396
-
-
Black, M.D.1
Varty, G.B.2
Arad, M.3
-
58
-
-
72449178338
-
The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice
-
Boulay D, Bergis O, Avenet P, et al. The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice. Neuropsychopharmacology 2010; 35: 416-27.
-
(2010)
Neuropsychopharmacology
, vol.35
, pp. 416-427
-
-
Boulay, D.1
Bergis, O.2
Avenet, P.3
-
59
-
-
3042691500
-
The synthesis and SAR of 2-arylsulfanyl-phenyl piperazinyl acetic acids as glyT-1 inhibitors
-
Smith G, Ruhland T, Mikkelsen G, et al. The synthesis and SAR of 2-arylsulfanyl-phenyl piperazinyl acetic acids as glyT-1 inhibitors. Bioorg Med Chem Lett 2004; 14: 4027-30.
-
(2004)
Bioorg Med Chem Lett
, vol.14
, pp. 4027-4030
-
-
Smith, G.1
Ruhland, T.2
Mikkelsen, G.3
-
60
-
-
0037343294
-
The glycine transporter-1 inhibitors NFPS and Org 24461: A pharmacological study
-
Harsing LG, Jr., Gacsalyi I, Szabo G, et al. The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study. Pharmacol Biochem Behav 2003; 74: 811-25.
-
(2003)
Pharmacol Biochem Behav
, vol.74
, pp. 811-825
-
-
Harsing Jr., L.G.1
Gacsalyi, I.2
Szabo, G.3
-
61
-
-
78651340371
-
Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone
-
Nagy K, Marko B, Zsilla G, et al. Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone. Neurochem Res 2010; 35: 2096-106.
-
(2010)
Neurochem Res
, vol.35
, pp. 2096-2106
-
-
Nagy, K.1
Marko, B.2
Zsilla, G.3
-
62
-
-
84876741336
-
Pre-clinical characterization of [(11)C]R05013853 as a novel radiotracer for imaging of the glycine transporter type 1 by positron emission tomography
-
Dec 10
-
Borroni E, Zhou Y, Ostrowitzki S, et al. Pre-clinical characterization of [(11)C]R05013853 as a novel radiotracer for imaging of the glycine transporter type 1 by positron emission tomography. Neuroimage 2011 Dec 10.
-
(2011)
Neuroimage
-
-
Borroni, E.1
Zhou, Y.2
Ostrowitzki, S.3
-
63
-
-
84855979108
-
Glycine reuptake inhibitor RG1678: A pharmacologic characterization of an investigational agent for the treatment of schizophrenia
-
Alberati D, Moreau JL, Lengyel J, et al. Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology 2012; 62: 1152-61.
-
(2012)
Neuropharmacology
, vol.62
, pp. 1152-1161
-
-
Alberati, D.1
Moreau, J.L.2
Lengyel, J.3
-
64
-
-
0033923220
-
Animal models for the negative symptoms of schizophrenia
-
Ellenbroek BA, Cools AR. Animal models for the negative symptoms of schizophrenia. Behav Pharmacol 2000; 11: 223-33.
-
(2000)
Behav Pharmacol
, vol.11
, pp. 223-233
-
-
Ellenbroek, B.A.1
Cools, A.R.2
-
65
-
-
78049250838
-
Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism
-
Neill JC, Barnes S, Cook S, et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther 2010; 128: 419-32.
-
(2010)
Pharmacol Ther
, vol.128
, pp. 419-432
-
-
Neill, J.C.1
Barnes, S.2
Cook, S.3
-
66
-
-
79957791056
-
Blockade of glycine transporter 1 by SSR-504734 promotes cognitive flexibility in glycine/NMDA receptor-dependent manner
-
Nikiforuk A, Kos T, Rafa D, et al. Blockade of glycine transporter 1 by SSR-504734 promotes cognitive flexibility in glycine/NMDA receptor-dependent manner. Neuropharmacology 2011; 61(1-2): 262-7.
-
(2011)
Neuropharmacology
, vol.61
, Issue.1-2
, pp. 262-267
-
-
Nikiforuk, A.1
Kos, T.2
Rafa, D.3
-
67
-
-
57349094379
-
Design of potent GlyT1 inhibitors: In vitro and in vivo profiles
-
Bridges TM, Williams R, Lindsley CW. Design of potent GlyT1 inhibitors: in vitro and in vivo profiles. Curr Opin Mol Ther 2008; 10(6): 591-601.
-
(2008)
Curr Opin Mol Ther
, vol.10
, Issue.6
, pp. 591-601
-
-
Bridges, T.M.1
Williams, R.2
Lindsley, C.W.3
-
68
-
-
77953545879
-
A randomized, double-blind, placebo-controlled comparison study of sarcosine (Nmethylglycine) and D-serine add-on treatment for schizophrenia
-
Lane HY, Lin CH, Huang YJ, et al. A randomized, double-blind, placebo-controlled comparison study of sarcosine (Nmethylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol 2010; 13: 451-60.
-
(2010)
Int J Neuropsychopharmacol
, vol.13
, pp. 451-460
-
-
Lane, H.Y.1
Lin, C.H.2
Huang, Y.J.3
-
69
-
-
1542617755
-
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia
-
Tsai G, Lane HY, Yang P, Chong MY, Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004; 55: 452-6.
-
(2004)
Biol Psychiatry
, vol.55
, pp. 452-456
-
-
Tsai, G.1
Lane, H.Y.2
Yang, P.3
Chong, M.Y.4
Lange, N.5
-
70
-
-
33748751382
-
Glycine transporter 1 inhibitor, Nmethylglycine (sarcosine), added to clozapine for the treatment of schizophrenia
-
Lane HY, Huang CL, Wu PL, et al. Glycine transporter 1 inhibitor, Nmethylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry 2006; 60: 645-9.
-
(2006)
Biol Psychiatry
, vol.60
, pp. 645-649
-
-
Lane, H.Y.1
Huang, C.L.2
Wu, P.L.3
-
71
-
-
36849071470
-
Sarcosine (N-methylglycine) treatment for acute schizophrenia: A randomized, double-blind study
-
Lane HY, Liu YC, Huang CL, et al. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry 2008; 63: 9-12.
-
(2008)
Biol Psychiatry
, vol.63
, pp. 9-12
-
-
Lane, H.Y.1
Liu, Y.C.2
Huang, C.L.3
-
72
-
-
80052965562
-
First-time-in-human study with GSK1018921, a selective GlyT1 inhibitor: Relationship between exposure and dizziness
-
Ouellet D, Sutherland S, Wang T, et al. First-time-in-human study with GSK1018921, a selective GlyT1 inhibitor: relationship between exposure and dizziness. Clin Pharmacol Ther 2011; 90: 597-604.
-
(2011)
Clin Pharmacol Ther
, vol.90
, pp. 597-604
-
-
Ouellet, D.1
Sutherland, S.2
Wang, T.3
-
73
-
-
84857039780
-
Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: Preliminary evidence
-
D'Souza DC, Singh N, Elander J, et al. Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence. Neuropsychopharmacology 2012; 37: 1036-46.
-
(2012)
Neuropsychopharmacology
, vol.37
, pp. 1036-1046
-
-
D'Souza, D.C.1
Singh, N.2
Elander, J.3
-
74
-
-
35748969317
-
The cognitive and negative symptoms in schizophrenia trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments
-
Buchanan RW, Javitt DC, Marder SR, et al. The cognitive and negative symptoms in schizophrenia trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007; 164: 1593-602.
-
(2007)
Am J Psychiatry
, vol.164
, pp. 1593-1602
-
-
Buchanan, R.W.1
Javitt, D.C.2
Marder, S.R.3
-
75
-
-
80053229847
-
Glycine transporter type 1 (GLYT1) inhibition RG1678: Results of the proof-ofconcept study for the treatment of negative symptoms in schizophrenia
-
Umbricht D, Martin-Facklam M, Pizzagalli E, et al. Glycine transporter type 1 (GLYT1) inhibition RG1678: Results of the proof-ofconcept study for the treatment of negative symptoms in schizophrenia. Schiz Bull 2011; 37(1): 324.
-
(2011)
Schiz Bull
, vol.37
, Issue.1
, pp. 324
-
-
Umbricht, D.1
Martin-Facklam, M.2
Pizzagalli, E.3
-
76
-
-
67649989298
-
Glycine transport inhibitors for the treatment of schizophrenia: Symptom and disease modification
-
Javitt DC. Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. Curr Opin Drug Discov Devel 2009; 12(4): 468-78.
-
(2009)
Curr Opin Drug Discov Devel
, vol.12
, Issue.4
, pp. 468-478
-
-
Javitt, D.C.1
-
77
-
-
77949372130
-
Recent progress in the discovery of nonsarcosine based GlyT1 inhibitors
-
Wolkenberg SE, Sur C. Recent progress in the discovery of nonsarcosine based GlyT1 inhibitors. Curr Top Med Chem 2010; 10(2): 170-86.
-
(2010)
Curr Top Med Chem
, vol.10
, Issue.2
, pp. 170-186
-
-
Wolkenberg, S.E.1
Sur, C.2
-
78
-
-
34547666657
-
Persistent negative symptoms in schizophrenia: An overview
-
Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull 2007 33(4): 1013-22.
-
(2007)
Schizophr Bull
, vol.33
, Issue.4
, pp. 1013-1022
-
-
Buchanan, R.W.1
-
79
-
-
84861339892
-
A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease
-
Harada K, Nakato K, Yarimizu J, et al. A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease. Eur J Pharmacol 2012; 685(1-3): 59-69.
-
(2012)
Eur J Pharmacol
, vol.685
, Issue.1-3
, pp. 59-69
-
-
Harada, K.1
Nakato, K.2
Yarimizu, J.3
|